Development of the high resolution melting method for genotyping CYP2C9*3 (1075A/C, rs1057910) and VKORC1 (-1639A/G, rs9923231).
- Author:
Guang-lin CUI
1
;
Hu DING
;
Yu-jun XU
;
Chen CHEN
;
Dao-wen WANG
Author Information
- Publication Type:Journal Article
- MeSH: Adult; Aged; Aged, 80 and over; Aryl Hydrocarbon Hydroxylases; genetics; Cytochrome P-450 CYP2C9; Dose-Response Relationship, Drug; Female; Freezing; Genotype; Genotyping Techniques; Humans; Male; Middle Aged; Mixed Function Oxygenases; genetics; Polymorphism, Restriction Fragment Length; Vitamin K Epoxide Reductases; Warfarin; administration & dosage; therapeutic use; Young Adult
- From: Chinese Journal of Cardiology 2012;40(6):477-481
- CountryChina
- Language:Chinese
-
Abstract:
OBJECTIVETo establish the high-resolution melting curve (HRM) approach for genotyping CYP2C9*3 (1075A/C, rs1057910) and VKORC1 (-1639A/G, rs9923231) and explore its value on estimation of the Warfarin initial dose in comparison with various traditional genotyping methods.
METHODSCYP2C9*3 (1075A/C, rs1057910) and VKORC1 (-1639A/G, rs9923231) genotyping was detected in 100 patients receiving Warfarin therapy by the newly developed HRM method and traditional genotyping methods including PCR-restriction fragment length polymorphism (PCR-RFLP), TaqMan probe and DNA sequencing.
RESULTSThe results of the genotypes obtained from above mentioned methods to detect CYP2C9*3 (1075A/C, rs1057910) and VKORC1 (-1639A/G, rs9923231) were similar and consistent. The HRM method is simpler, more economical, and faster compared to the traditional methods. The frequencies of the VKORC1-1639 AA, AG, GG genotypes from these 100 clinical samples were 73 (73%), 23 (23%), 4 (4%), respectively; Frequencies of the CYP2C9 1075 AA, AC, CC genotypes were 94(94%), 6 cases (6%), 0, respectively.
CONCLUSIONSHRM approach can effectively detect CYP2C9*3 (1075A/C, rs1057910) and VKORC1 (-1639A/G, rs9923231) polymorphisms and this method is simpler, more economical, and faster compared to the traditional methods for detecting CYP2C9*3 (1075A/C, rs1057910) and VKORC1 (-1639A/G, rs9923231) polymorphisms.
